|Bid||0.30 x 0|
|Ask||0.34 x 0|
|Day's Range||0.29 - 0.30|
|52 Week Range||0.14 - 0.60|
|Beta (3Y Monthly)||-0.30|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||19.26|
If you want to know who really controls Immuron Limited (ASX:IMC), then you’ll have to look at the makeup of its share registry. Institutions will often hold stock in biggerRead More...
Travelan® prevented clinical shigellosis (bacillary dysentery) in 75% of Travelan® treated NHPs compared to placebo. NASDQ: IMRN), an Australian microbiome biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of many gut mediated pathogens, today is pleased to provide shareholders with an update on the company’s cooperative research and development agreements with the US Department of Defense (US DoD).
Global Immuron Ltd sales revenue reached an AU$2million milestone continuing its upward trend and enjoying a 29% sales increase compared to FY17. US Travelan® sales continue to exceed expectations growing to AU$765k which represents a 114% increase over FY17. MELBOURNE, Australia, July 25, 2018 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (IMRN), an Australian microbiome biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases, is today pleased to announce the sales results of Travelan®, its commercially available, over-the-counter gastrointestinal and digestive health supplement, for the fiscal year ended June 30th, 2018.
Immuron Limited (ASX:IMC) (IMRN) is an Australian microbiome biopharmaceutical Company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases. The Company is pleased to announce that the European Patent Office (EPO) has decided to Grant a patent for the use of a composition for the treatment of Non-alcoholic steatohepatitis (NASH). This patent (EPO Grant No. 2424890) is entitled “Anti-LPS enriched immunoglobulin preparations for the treatment and/or prophylaxis of a pathologic disorder”).
Three US Defense Health funded research projects on Travelan ® successfully completed Studies commissioned by the US Department of Defense to evaluate Travelan ®’ s ability to neutralise pathogenic bacteria ...